- €518.45m
- €644.51m
- €274.63m
- 33
- 25
- 32
- 18
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 20.31 | ||
PEG Ratio (f) | 0.72 | ||
EPS Growth (f) | 39.17% | ||
Dividend Yield (f) | 2.34% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.3 | ||
Price to Tang. Book | 4.87 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 2.04 | ||
EV to EBITDA | 17.89 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 5.5% | ||
Return on Equity | 5.46% | ||
Operating Margin | 7.46% |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | €m | 187.82 | 214.16 | 250.1 | 287.33 | 274.63 | 268.38 | 284 | 5.77% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -61.66 | +58.37 | +66.78 | +43.33 | -28.42 | -37.14 | +39.17 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Stratec SE is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of in-vitro diagnostics and life sciences in Germany and internationally. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.
Directors
- Stefanie Remmele CSU (43)
- Marcus Wolfinger CMG (53)
- Frank Hiller VSU (54)
- Robert Siegle FID (53)
- Claus Vielsack MGB (53)
- Rolf Vornhagen IND (67)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- November 27th, 2018
- Public Since
- August 25th, 1998
- No. of Employees
- 1,532
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- XETRA
- Shares in Issue
- 12,155,942
- Address
- Gewerbestr. 37, BIRKENFELD, 75217
- Web
- https://www.stratec.com/
- Phone
- +49 708279160
- Contact
- Jan Keppeler
- Auditors
- EBNER STOLZ GMBH & CO. KG WIRTSCHAFTSPRUFUNGSGESELLSCHAFT ST
Upcoming Events for SBS
Stratec SE METZLER Small Cap Days
Q1 2024 Stratec SE Earnings Release
Q1 2024 Stratec SE Earnings Call
Stratec SE at UBS Pan European Small and Mid-Cap Conference
Stratec SE at Berenberg Diagnostics Conference
Stratec SE Annual Shareholders Meeting
Stratec SE Annual Shareholders Meeting
Dividend For SBSG.DE - 0.5500 EUR
Stratec SE at Warburg Highlights Conference
Half Year 2024 Stratec SE Earnings Release
Similar to SBS
Aap Implantate AG
XETRA
Bio-Gate AG
XETRA
FAQ
As of Today at 18:20 UTC, shares in Stratec SE are trading at €42.65. This share price information is delayed by 15 minutes.
Shares in Stratec SE last closed at €42.65 and the price had moved by -35.28% over the past 365 days. In terms of relative price strength the Stratec SE share price has underperformed the FTSE Global All Cap Index by -44.18% over the past year.
The overall consensus recommendation for Stratec SE is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Stratec SE dividend yield is 2.27% based on the trailing twelve month period.
Last year, Stratec SE paid a total dividend of €0.97, and it currently has a trailing dividend yield of 2.27%.Looking ahead, shares in Stratec SE are due to go ex-dividend on 2024-05-20 and the next dividend pay date is 2024-05-22.
Stratec SE are due to go ex-dividend on 2024-05-20 and the next dividend pay date is 2024-05-22. The historic dividend yield on Stratec SE shares is currently 2.27%.
To buy shares in Stratec SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €42.65, shares in Stratec SE had a market capitalisation of €518.45m.
Here are the trading details for Stratec SE:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: SBS
Based on an overall assessment of its quality, value and momentum Stratec SE is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Stratec SE is €49.60. That is 16.3% above the last closing price of €42.65.
Analysts covering Stratec SE currently have a consensus Earnings Per Share (EPS) forecast of €1.51 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Stratec SE. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -15.88%.
As of the last closing price of €42.65, shares in Stratec SE were trading -8.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Stratec SE PE ratio based on its reported earnings over the past 12 months is 20.31. The shares last closed at €42.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Stratec SE's management team is headed by:
- Stefanie Remmele - CSU
- Marcus Wolfinger - CMG
- Frank Hiller - VSU
- Robert Siegle - FID
- Claus Vielsack - MGB
- Rolf Vornhagen - IND